100%immune response rate! Chen Wei academician team Lancet reports results of the world's first phase I clinical trial of the world's first new crown vaccine

On May 22, The Institute of Military Medicine, DrChen Wei, and others published the results of the world's first phase I clinical trial of the world's first new crown vaccine online in The Lancet: 108 healthy adult volunteers produced a significant cellular immune response 28 days after vaccinationThe study showed that healthy adult volunteers who received the new coronavirus Ad5-borne vaccine showed significant antibody growth in their bodies on the 14th day of vaccination and peaked on the 28th day of vaccination;volunteers did not experience serious adverse reactions within 28 days of vaccinationThe proportion of patients with at least one adverse reaction within 7 days of vaccination in the low, medium and high-dose groups was 83%, 83% and 75%, respectivelythe most common adverse reaction at the vaccination site was pain, which was reported by 54% of the total inoculated populationThe most common systemic adverse reactions were fever (46%), followed by fatigue (44%), headache (39%) and muscle pain (17%)Most adverse reactions are mild or moderateresearchers noted that the study is the first reported phase 1 clinical trial of anew-based coronavirus Ad5-borne vaccine, which initially shows that the vaccine is well tolerated and can induce a rapid immune responseThe team will continue to follow up on the volunteers who were vaccinated against the new crown for at least six months, when the safety and effectiveness of the vaccine will be further evaluated, according to the Lancet, The Study's director, DrChen Wei, said the Phase 1 clinical trial was an important milestone and showed the potential for further research on the new type 5 adenovirus vectorHowever, the results of these trials should be interpreted with caution, as the challenges of developing a new coronavirus are unprecedented and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from neo-coronavirus infectionsthe study screened 195 healthy adult volunteers from March 16 to March 27, 2020 in Wuhan, Hubei Province, and eventually included 108 people with an average age of 36.3 years, with men and women accounting for half of each, and 36 cases in the low, medium and high-dose vaccination groupsit is understood that Chen Wei's team launched a Phase II clinical trial of the new crown vaccine on April 12, incorporating 508 volunteersSource: [1] Safety, Tolerability, and Immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation- label, non-randomised, first-in-human trial Lancet, May 22, 2020 The Lancet releases results of Chen Wei's team's new crown vaccine trial News China Circulation Magazine Source: Zhu